Innate Pharma (IPHA) Free Cash Flow (2019 - 2025)

Innate Pharma has reported Free Cash Flow for 7 years, with the latest figure at -$61.2 million in Q4 2025.

• For the quarter ending Q4 2025, Free Cash Flow fell 781.09% year-over-year to -$61.2 million; the trailing twelve-month figure through Dec 2025 stood at -$68.2 million (down 26.87% YoY), and the FY2025 full-year result was -$61.4 million, down 688.63% from the prior year.
• Free Cash Flow for Q4 2025 stood at -$61.2 million, down from -$7.0 million in the prior quarter.
• The five-year high for Free Cash Flow was $448163.8 in Q2 2022, with the low at -$65.8 million in Q4 2021.
• Historically, Free Cash Flow has averaged -$29.6 million across 5 years, with a median of -$26.8 million in 2023.
• Annual changes were most pronounced in 2022 — Free Cash Flow soared 101.2% — and 2023, when it tumbled 2810.63%.
• Innate Pharma's Free Cash Flow stood at -$65.8 million in 2021, then surged by 71.13% to -$19.0 million in 2022, then plunged by 82.42% to -$34.7 million in 2023, then soared by 79.94% to -$7.0 million in 2024, then plunged by 781.09% to -$61.2 million in 2025.
• The last three Free Cash Flow figures came in at -$61.2 million (Q4 2025), -$7.0 million (Q4 2024), and -$34.7 million (Q4 2023), per Business Quant data.